The global in vitro diagnostics market was valued at USD 108.30 billion in 2024 and is expected to reach USD 150.13 billion by 2030, growing at a CAGR of 5.62% from 2025 to 2030. Market expansion is driven by the rising global demand for accurate, rapid, and personalized diagnostic solutions, supported by continuous advancements in medical and analytical technologies.
Key growth drivers include the increasing prevalence of chronic and infectious diseases, rapid innovation in diagnostic platforms, and the transition toward value-based healthcare models that prioritize early detection and preventive care. The integration of digital health solutions, artificial intelligence (AI), and data analytics into diagnostic systems is significantly improving test accuracy, workflow efficiency, and clinical decision-making. In addition, the growing adoption of point-of-care testing, the rise of personalized medicine, expanding healthcare access in emerging economies, and enhanced pandemic preparedness initiatives are collectively strengthening market penetration and opening new growth avenues for industry participants.
Key Market Trends & Insights
- North America dominated the in vitro diagnostics market in 2024, accounting for a 47.43% revenue share.
- Asia Pacific is the fastest-growing regional market, projected to expand at a CAGR of 6.57% over the forecast period.
- By product, the reagents segment held the largest market share of 65.54% in 2024, driven by recurring demand across testing procedures.
- By technology, immunoassay diagnostics accounted for the highest revenue share in 2024.
- By application, the infectious diseases segment dominated the in vitro diagnostics industry in 2024.
Download a free sample PDF of the In Vitro Diagnostics Market Intelligence Study by Grand View Research.
Market Size & Forecast
- 2024 Market Size: USD 108.30 Billion
- 2030 Projected Market Size: USD 150.13 Billion
- CAGR (2025–2030): 5.62%
- North America: Largest market in 2024
- Asia Pacific: Fastest-growing market
Competitive Landscape
The in vitro diagnostics market is characterized by the presence of well-established multinational players alongside a growing number of innovative emerging companies. Leading firms such as Abbott, bioMérieux, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific, Inc., and Bio-Rad Laboratories, Inc. invest heavily in advanced technologies, automation, and data infrastructure to efficiently manage large-scale diagnostic operations.
Market participants are actively pursuing strategic initiatives, including new product launches, mergers and acquisitions, and partnerships, to strengthen their technological capabilities, diversify product offerings, and enhance global reach.
Emerging players such as ARUP Laboratories, RayBiotech, Inc., Randox Laboratories Ltd., Everlywell, Orreco, and Biostarks are focusing on product differentiation and innovation to gain market traction. These companies emphasize the development of novel, high-precision IVD solutions and frequently collaborate with research institutions, government agencies, and global healthcare leaders to expand their footprint across high-growth markets.
Key Players Include:
- Abbott
- Bio-Rad Laboratories, Inc.
- Siemens Healthineers AG
- bioMérieux
- BD
- QIAGEN
- Quidel Corporation
- F. Hoffmann-La Roche Ltd.
- Danaher
- Quest Diagnostics Incorporated
- Agilent Technologies, Inc.
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
Conclusion
The global in vitro diagnostics market is poised for sustained growth, underpinned by rising disease burden, technological innovation, and the increasing shift toward personalized and preventive healthcare. The integration of AI-driven diagnostics, digital platforms, and point-of-care solutions is expected to further transform the diagnostic landscape. With strong demand across both developed and emerging regions, and continued investments by established and emerging players, the IVD market is set to remain a critical pillar of modern healthcare systems throughout the forecast period.
No comments:
Post a Comment